About this trial
The aim of this study is evaluating and safety and efficacy between the modified double snare EMR and ESD. It is intended to prove that for rectal neuroendocrine tumors within 1 cm, the complete resection rate of the mDS-EMR is not inferior to that of ESD, but may with shorter operation time, lower complication rate and lower treatment cost.
Eligibility criteria
Qualifiers
Typical rectal neuroendocrine tumors by endoscopy (within 15cm from the anal verge, yellowish subepithelial elevation with a smooth surface, and dilated blood vessels in some areas).
The maximum diameter of the lesion is smaller than 1cm by preoperative endoscopic assessment.
Lesion is located within the mucosal and submucosal layer by preoperative endoscopic assessment.
Patients can understand and sign the informed consent.
Disqualifiers
Poor coagulation function(PT>15 seconds or APTT>45 seconds or INR>2.0)
With severe cardiovascular or cerebrovascular diseases and cannot tolerate operation( with a history of stroke or myocardial infarction within the past month or with severe heart failure and cardiac function grade III)
Indication of metastasis by preoperative imaging examinations
With more than or equal to 2 rectal neuroendocrine tumors
Trial design
Treatments tested in this trial
- modified double snare assisted endoscopic mucosal resection
- endoscopic submucosal dissection